NPPA slashes cancer drug MRPs by up to 93%; Thiotepa cut by Rs.72,921

What happened

India's drug price regulator cut maximum retail prices, the most a shop can charge, by up to 93.3% on 543 versions of 137 cancer drugs, effective 9 November. A 100 mg thiotepa vial falls by Rs.72,921.53 to Rs.7,150.33.

Confirmed

Global impact / market context

Lower cancer drug prices reduce what patients pay and can shrink revenue per sale for makers and sellers of these medicines. NPPA expects Rs.2,500 crore to Rs.3,500 crore in yearly patient savings, money that could shift toward other spending.

Analyst inference

The order targets drugs without a government-fixed price ceiling, while the Supreme Court weighs wider controls after reports of hospital markups. This signals tighter pricing scrutiny for medicine sellers, which could pressure margins, the profit per sale, at hospitals and pharmacies.

Analyst inference

What to watch

1. New maximum retail prices take effect on 9 November for 543 versions of 137 cancer drugs, including thiotepa and palbociclib. Confirmed
2. The Supreme Court is considering wider controls on medicine prices, which could extend regulation beyond the drugs covered by this order. Proposed
3. Watch whether hospitals and drugmakers absorb the cuts or pass them through, affecting profit per sale and capital spending plans. Analyst inference

Evidence

• Original source link unavailable